Estudo de Usabilidade dos Sensores e da Aplicação eMOM GDM (eMOMGDM)
Estudo de Usabilidade dos Sensores e da Aplicação eMOM GDM eHealth no Tratamento da Diabetes Gestacional - eMOM GDM -Study
The principal aim of the eMOM GDM-project is to evaluate the effect of the eMOM GDM -application and the integrated service concept model on maternal and neonatal outcomes.
In the first phase of the project the investigators evaluate the usability, functionality and acceptability of developed eMOM GDM application and used sensors (continuous glucose meter, accelerometer, speech-enabled food record, optical pulse, beat-to-beat heart rate). Two different user interfaces (one for the women with GDM and one for the health care professionals) of the eMOM GDM application will we be developed and evaluated.
Visão geral do estudo
Status
Status
Condições
Condições
Descrição detalhada
The first phase of the eMOM GDM -project consists of two parts.
Phase 1.1. the usability of the sensors will be evaluated by asking participants with GDM diagnosis (n = up to 10) to use the sensors (Garmin Vivosmart 3, Medtronic Guardian Connect, Firstbeat Bodyguard 2, and Exced) and by collecting participants' blood glucose values from glucose meter (Contour Next ONE) for one week. Participants fill out a logbook for physical activity and sleeping for seven days, and a logbook for diet for three days during the study period. For ensuring the quality of food record a researcher will phone interview the participant based on her diet recordings.
Before starting using the sensors, the participants will fill Background questionnaire and Technology acceptance questionnaire (UTAUT). After the usage period, the participants will fill the same Technology acceptance questionnaire (UTAUT) and take part in semi-structured interview. The interview has to parts. In the first part, participants will be interviewed about the acceptability of sensors. In the second part, researcher will show a non-functional prototype of eMoM GDM application to the participant and will ask predetermined questions. Interview will be recorded and data obtained from the interviews will be transcribed for analysis.
Phase 1.2. will define major usability issues with different versions of functional prototypes of eMOM GDM application developed in the project before moving to phase 2 of the study. General pregnant women (n = up to 30 in total) and GDM women (n=up to 10) will use the available version of the application for one week, and afterward the participants with GDM will take part in semi-structured interview. Interview will be recorded and data will be transcribed for analysis. General pregnant women will fill out a web form of usability of the application after application week. Based on the responses of the form, the participants may be contacted for further inquiries about the usability issues they have reported. For ensuring the quality of food record a researcher will phone interview all participants based on her diet recordings.
In Phase 1.3 user requirements for the professional eMOM GDM application will be collected. The first aim of this evaluation is to define what features the application should have. These user requirements are collected with a semi-structured interview. Before the interview, background of the 15-20 nurses/midwifes is asked with background questionnaire on profession. In the interviews, the questions are predetermined, but some flexibility is allowed. Interviews will be recorded and data obtained from the interviews will be transcribed for analysis.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Contactos e Locais
Locais de estudo
-
-
Helsinki
-
Helsinki, Helsinki, Finlândia, 00029
- HUS
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
- General population of pregnant women
- Pregnant women without gestational diabetes in previous pregnancy
- Pregnant women with or without gestational diabetes in previous pregnancies
- Health care professionals (nurses/midwives)
Descrição
Inclusion Criteria:
- General pregnant women at gestational week >=24
- GDM women without a prior GDM at gestational week >=24
- GDM women with or without a prior GDM at gestational week >=24
Exclusion Criteria:
- Type 1 Diabetes Mellitus
- Type 2 Diabetes Mellitus
- Use of medication that influences glucose metabolism in the beginning of the study (e.g. oral corticosteroids, metformin,insulin)
- Multiple Pregnancy
- Current substance abuse
- Severe psychiatric disorder
- Significant difficulty in cooperating (e.g. inadequate Finnish language skills)
- Significant physical disabilities
For health care professionals
Inclusion Criteria:
- Consult and treat women with GDM regularly
Exclusion Criteria:
- Inadequate Finnish language skills
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: OTHER
- Perspectivas de Tempo: PROSPECTIVE
Número de grupos/coortes
Coortes e Intervenções
Grupo / CoorteGrupo / Coorte |
|---|
|
Women with gestational diabetes without a prior GDM
The investigators will evaluate the usability of the sensors and define what features the application should have and how the data should be presented to the users. Participants (n=up to 10) use the sensors for one week and fill out logbooks for physical activity, sleep and diet. Participants fill questionnaires before and after the usage period, and take part in semi-structured interview. |
|
Women with gestational diabetes with or without a prior GDM
The investigators define major usability issues with different versions of functional prototypes of eMOM GDM application developed in the project before moving to phase 2 of the study. GDM women (n=up to 12) will use the available version of the application for one week, and afterward the participants with GDM will take part in semi-structured interview. |
|
General pregnant women
The investigators will define major usability issues with different versions of functional prototypes of eMOM GDM application developed in the project before moving to phase 2 of the study. General pregnant women (n=up to 30) will use the available version of the application for one week, and afterward the general pregnant women will fill out a web form of usability of the application after the application week. |
|
Health care professionals
Nurses/midwifes (n=up to 20) will be interviewed for collecting user requirements for the professional eMOM GDM application in semi-structured interviews. |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Basic version of the eMOM GDM application has developed
Prazo: 1 week
|
Goal of the eMOM GDM -project is develop an application for gestational diabetes. The basic version of eMOM GDM application is ready to use in Phase 2 when in all sectors of Software Usability Measurement Inventory (SUMI) scale have mean of 50 or higher during the same development period (sprint). SUMI is a rigorously tested and proven method of measuring software quality from the end user's point of view. Sectors which SUMI measures are efficiency, affect, helpfulness, control, learnability, and global usability of software. |
1 week
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Acceptability of sensors assessed by UTAUT questionnaire
Prazo: 1 week
|
The acceptability of the sensors (Medtronic Guardian Connect, Garmin Vivosmart 3, Firsbeat Bodyguard 2, UKK Exsed, Ascensia Contour Next One) will be assessed by UTAUT (Unified Theory of Acceptance and Use of Technology)-questionnaire. UTAUT-questionnaire will be common for each sensor, so UTAUT will not be conducted for each sensor separately. The answers applied quantitative way so investigators are able analyzed change of acceptability of sensors caused by the intervention. Results applied to development of the eMOM GDM application. |
1 week
|
|
Acceptability of sensors and eMOM GDM prototype application assessed by UTAUT questionnaire
Prazo: 1 week
|
The acceptability of the sensors (Garmin Vivosmart 3, Medtronic Guardian Connect, Ascensia Contour Next One, Speechgrinder Snackchat) and the eMOM GDM prototype application will be assessed by UTAUT (Unified Theory of Acceptance and Use of Technology) questionnaire. UTAUT questionnaire will be common for each sensor and the application, so UTAUT will not be conducted for each sensor separately. The answers applied quantitative way so investigators are able analyzed change of acceptability of sensors and application caused by the intervention. Results applied to development of the eMOM GDM application. |
1 week
|
|
Usability of sensors and their current applications
Prazo: 1 week
|
Semi-structured interview of usability of chosen sensors and their current applications (Medtronic Guardian Connect, Garmin Vivosmart 3, Firsbeat Bodyguard 2, UKK Exsed, Ascensia Contour Next One). General questions related to the usability issues of sensors and their current applications. Sensors specific questions relate to usage of specific sensor and features of its application. The answers of participants give for investigators the guideline for development of eMOM GDM application. The answers itself won't be scaled, there isn't wrong or correct answers. Answers which repeat the most commonly in the interviews are the most common issues and they will have a higher priority in the guideline than answers which arises only in one interview. |
1 week
|
|
First impressions of a partially functional prototype of the eMOM GDM
Prazo: 1 week
|
First impressions of eMOM GDM application questions relate to usability and acceptability of the eMOM GDM application which is under the development. The answers of participants give for investigators the guideline for development of eMOM GDM application. The answers itself won't be scaled, there isn't wrong or correct answers. Answers which repeat the most commonly in the interviews are the most common issues and they will have a higher priority in the guideline than answers which arises only in one interview. |
1 week
|
|
Usability of eMOM GDM prototype application
Prazo: 1 week
|
Usability of the eMOM GDM prototype application will be assessed with a semi-structured interview. The interview has general questions about the usability issues of sensors (Garmin Vivosmart 3, Medtronic Guardian Connect, Ascensia Contour Next One, Speechgrinder Snackchat) and the eMOM GDM prototype application, and tasks which the participants try to solve using the eMOM GDM prototype application. The answers used as the guideline for development of eMOM GDM application. |
1 week
|
|
Technical functionality of eMOM GDM application
Prazo: 1 week
|
Technical functionality of eMOM GDM application will be assessed by a web-based survey. The web-survey asks feedback from the eMOM GDM prototype application, and Garmin Vivosmart 3 bracelet, and there are 20 questions from Software Usability Measurement Inventory (SUMI) which the participant answers agree, disagree or not sure. This survey used as a guideline for development of eMOM GDM application. The answers tell how much major problems investigators still have in the eMOM GDM prototype application. |
1 week
|
|
User requirements for professional eMOM GDM application
Prazo: 2 hours
|
User requirements will be collected through a semi-structured interviews. The interviews will be transcribed and a a framework analysis will be conducted to find the most important features. The answers used as the guideline for development of professional eMOM GDM application. |
2 hours
|
Outras medidas de resultado
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Continuous glucose levels dataset
Prazo: 1 week
|
Dataset from Medtronic Guardian Connect glucose meter |
1 week
|
|
Physical activity dataset
Prazo: 1 week
|
Dataset from Vivosmart 3, ExSed, Firstbeat Bodyguard 2, and physical activity logbook |
1 week
|
|
Sleep dataset
Prazo: 1 week
|
Dataset from Vivosmart 3, Firstbeat Bodyguard 2, and sleep logbook |
1 week
|
|
Recovery dataset
Prazo: 1 week
|
Dataset from Vivosmart 3 and Firstbeat Bodyguard 2 |
1 week
|
|
Stress dataset
Prazo: 1 week
|
Dataset from Vivosmart 3 and Firstbeat Bodyguard 2 |
1 week
|
|
Heart beat dataset
Prazo: 1 week
|
Dataset from Vivosmart 3 and Firstbeat Bodyguard 2 |
1 week
|
|
Nutrition dataset
Prazo: 1 week
|
Dataset from nutrition logbook |
1 week
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Diretor de estudo: Seppo T Heinonen, prof, Helsinki University Hospital, Women's Hospital
Publicações e links úteis
Publicações Gerais
- Kyto M, Koivusalo S, Ruonala A, Stromberg L, Tuomonen H, Heinonen S, Jacucci G. Behavior Change App for Self-management of Gestational Diabetes: Design and Evaluation of Desirable Features. JMIR Hum Factors. 2022 Oct 12;9(4):e36987. doi: 10.2196/36987.
- Kyto M, Koivusalo S, Tuomonen H, Stromberg L, Ruonala A, Marttinen P, Heinonen S, Jacucci G. Supporting the Management of Gestational Diabetes Mellitus With Comprehensive Self-Tracking: Mixed Methods Study of Wearable Sensors. JMIR Diabetes. 2023 Oct 31;8:e43979. doi: 10.2196/43979.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Real)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- HUS/2165/2018
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .